HAE Price Prediction Next Week
Technical Analysis: Based on recent price action, HAE shows a bearish trend with significant downward pressure. The stock has declined from $74.86 to $65.26 over the past month.
- RSI (14) at 46.42 indicates neutral momentum but trending downward
- MACD shows bearish divergence with -1.86 and weakening momentum
- Price is trading below all major moving averages (SMA 20/60/200)
- Bollinger Bands show price near the lower band with BBP at 0.57
News Impact: Recent negative catalysts include:
- Bank of America downgraded HAE to Underperform with $68 price target (down from $95) citing weaker Q3 performance
- JMP Securities lowered price target to $100 from $125 while maintaining Outperform rating
- Q3 revenue missed forecasts with underperformance in key plasma and Vascade segments
- Potential 25% tariffs on Canada/Mexico could negatively impact operations due to high exposure
Price Projection: For next week's trading (March 4-8, 2025):
- Resistance levels: $66.10 (Fibonacci R1), $67.28 (Fibonacci R2)
- Support levels: $62.28 (Fibonacci S1), $61.10 (Fibonacci S2)
Given the technical weakness and negative fundamental catalysts, HAE is likely to test lower support levels. Price target range for next week: $61-63.
Recommendation: SELL
- Multiple downgrades and missed earnings create significant downside risk
- Technical indicators suggest continued weakness
- Fibonacci projections indicate more downside potential
- Consider exiting positions or establishing short positions with tight stops above $67
HAE Similar Chart Price Prediction
The price of HAE is predicted to go up 9.44%, based on the high correlation periods with CRVL. The similarity of these two price pattern on the periods is 97.96%.
HAE
CRVL
Up: 9.44%Similarity: 97.96%
HAE Revenue Forecast
HAE EPS Forecast
HAE FAQs
What is bull’s view on HAE?
What is bear's view on HAE?
What is HAE revenue forecast for next quarter？
What is HAE eps forecast for next quarter？
HAE Analyst's Forecast
Rohin Patel
JP Morgan
Buy
2024-12-06
Price Target
$116
Upside
+42.87%
JPMorgan analyst Rohin Patel initiated coverage of Haemonetics with an Overweight rating and $116 price target. Haemonetics has "multiple shots on goal" that should support sales acceleration and healthy cash flow generation over the coming years as the mix shifts to premium, higher margin interventional products, and the commercial plasma business normalizes, the analyst tells investors in a research note. The firm thinks a "strong" fiscal Q2 and underlying business trends should support high-20%'s operating margin next year, with further upside thereafter.
Andrew Cooper
Raymond James
Buy → Strong Buy
2024-11-08
Price Target
$120
Upside
+37.27%
